Abstract
Cancer cells enter the circulation and attach to endothelial cells to pass through them and migrate over a distance to enter the tissue of the metastatic organ to proliferate there. In the same way, neutrophils drift in blood and adhere loosely to adhesive molecules on the endothelial cells in an inflamed area. They roll along the endothelial cells and then adhere closely to the endothelial cells to penetrate vessel wall. Neutrophils can destroy the basement membrane and migrate over a distance to fight against foreign bodies. Thus, the process that both of them follow is quite the same. Neutrophil elastase (NE) is a neutral serine protease which has broad substrate specificity under the physiological conditions, and its excessive production results in digestion of not only elastin, but also other extracellular matrix proteins. This minireview summarizes our recent experimental and clinical studies on NE/NE inhibition and cancer/cancer treatment based on our original view point.
Keywords: Neutrophil Elastase, Cancer Therapy, endothelial cells, metastatic organ, neutral serine protease, plasminogen activator (PA)
Current Enzyme Inhibition
Title: Neutrophil Elastase Inhibition: A New Cancer Therapy
Volume: 4 Issue: 2
Author(s): Takashi Sato, Miwa Yoshida, Satoshi Takahashi, Takashi Fukutomi and Jun-Ichi Yamashita
Affiliation:
Keywords: Neutrophil Elastase, Cancer Therapy, endothelial cells, metastatic organ, neutral serine protease, plasminogen activator (PA)
Abstract: Cancer cells enter the circulation and attach to endothelial cells to pass through them and migrate over a distance to enter the tissue of the metastatic organ to proliferate there. In the same way, neutrophils drift in blood and adhere loosely to adhesive molecules on the endothelial cells in an inflamed area. They roll along the endothelial cells and then adhere closely to the endothelial cells to penetrate vessel wall. Neutrophils can destroy the basement membrane and migrate over a distance to fight against foreign bodies. Thus, the process that both of them follow is quite the same. Neutrophil elastase (NE) is a neutral serine protease which has broad substrate specificity under the physiological conditions, and its excessive production results in digestion of not only elastin, but also other extracellular matrix proteins. This minireview summarizes our recent experimental and clinical studies on NE/NE inhibition and cancer/cancer treatment based on our original view point.
Export Options
About this article
Cite this article as:
Sato Takashi, Yoshida Miwa, Takahashi Satoshi, Fukutomi Takashi and Yamashita Jun-Ichi, Neutrophil Elastase Inhibition: A New Cancer Therapy, Current Enzyme Inhibition 2008; 4 (2) . https://dx.doi.org/10.2174/157340808785107556
DOI https://dx.doi.org/10.2174/157340808785107556 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development and Application of Fourier-Transform Infrared Chemical Imaging of Tumour in Human Tissue
Current Medicinal Chemistry Nanoparticles as Novel Carrier for Brain Delivery: A Review
Current Pharmaceutical Design The Ligand Binding Region of the Sigma-1 Receptor: Studies Utilizing Photoaffinity Probes, Sphingosine and N-Alkylamines
Current Pharmaceutical Design Editorial (Thematic Issue: Antitarget Therapies: New Frontiers in the Treatment of Cancer)
Anti-Cancer Agents in Medicinal Chemistry It Takes Two to Tango: The Structure and Function of LIM, RING, PHD and MYND Domains
Current Pharmaceutical Design Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Recent Developments in Breast Tomosynthesis Imaging
Recent Patents on Medical Imaging MicroRNAs and Physical Activity
MicroRNA Dendritic Cells in Esophageal Adenocarcinoma: The Currently Available Information and Possibilities to use Dendritic Cells for Immunotherapeutic Approaches
Current Pharmaceutical Design Detection of Melatonin Production from the Intestinal Epithelium Using Electrochemical Methods
Current Pharmaceutical Design Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Glycosides from Medicinal Plants as Potential Anticancer Agents: Emerging Trends Towards Future Drugs
Current Medicinal Chemistry Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Regulatory T Cells: Major Players in the Tumor Microenvironment
Current Pharmaceutical Design Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models
Current Medicinal Chemistry Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Current Cancer Therapy Reviews Recent Patents on Physical, Mineral & Organic Acid Composition of Golden Delicious and Red Delicious Apples (Malus×Domestica Borkh) Grown in the West of Iran
Recent Patents on Food, Nutrition & Agriculture